Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Ng, Journal (Endocrinology, Volume 142, Issue 12, December 2001, Pages 51825189)
Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)
doi:10.1016/j.tibs.2013.09.001 Study: Mitochondrial dysfunction linked to aging can be mitigated by antioxidant support
Study design and participants The REDEFINE-1 trial is a large phase 3 study testing treatments for obesity
Org Prep Proc Int
Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK
US$ 22.56
US$ 24.50
US$ 25.11
US$ 21.33
